Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Free Cash Flow (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Free Cash Flow for 4 consecutive years, with -$9.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 145.35% year-over-year to -$9.8 million, compared with a TTM value of -$69.8 million through Sep 2025, up 26.46%, and an annual FY2024 reading of -$69.0 million, up 64.29% over the prior year.
  • Free Cash Flow was -$9.8 million for Q3 2025 at Atara Biotherapeutics, down from -$7.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$4.0 million in Q3 2024 and bottomed at -$87.1 million in Q1 2022.
  • Average Free Cash Flow over 4 years is -$38.8 million, with a median of -$38.6 million recorded in 2023.
  • The sharpest move saw Free Cash Flow surged 92.22% in 2024, then tumbled 145.35% in 2025.
  • Year by year, Free Cash Flow stood at -$56.9 million in 2022, then rose by 11.24% to -$50.5 million in 2023, then surged by 51.38% to -$24.6 million in 2024, then soared by 60.15% to -$9.8 million in 2025.
  • Business Quant data shows Free Cash Flow for ATRA at -$9.8 million in Q3 2025, -$7.3 million in Q2 2025, and -$28.1 million in Q1 2025.